Literature DB >> 27612681

The Use of Exosomes as Biomarkers for Evaluating and Monitoring Critically Ill Polytrauma Patients with Sepsis.

Marian Ticlea1, Lavinia Melania Bratu2, Florian Bodog1, Ovidiu Horea Bedreag3,4, Alexandru Florin Rogobete5,6, Zorin Petrisor Crainiceanu3.   

Abstract

Regarding genetic biomarkers for early assessment and monitoring the clinical course in polytrauma patients with sepsis, in recent years a remarkable evolution has been highlighted. One of the main representatives is the exosome miRNAs. In this paper, we would like to present in more details the various methods of using exosome miRNAs as a biomarker for monitoring polytrauma patients with sepsis, as well as establishing a belated outcome by aggregating the entire clinical aspects. The use of exosome miRNAs for late evaluating and monitoring the clinical evolution of polytrauma patients can bring significant improvements in current clinical practice through the optimization and modulation of intensive care according to the needs of each patient individually.

Entities:  

Keywords:  Critically ill polytrauma patient; Epigenetic biomarkers; Exosomal miRNAs; Sepsis

Mesh:

Substances:

Year:  2016        PMID: 27612681     DOI: 10.1007/s10528-016-9773-6

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  3 in total

1.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29

2.  Identification of potential genes and miRNAs associated with sepsis based on microarray analysis.

Authors:  Yin Li; Fengxia Zhang; Yan Cong; Yun Zhao
Journal:  Mol Med Rep       Date:  2018-03-01       Impact factor: 2.952

Review 3.  Alarming Cargo: The Role of Exosomes in Trauma-Induced Inflammation.

Authors:  Sarah A Walsh; Benjamin W Hoyt; Cassie J Rowe; Devaveena Dey; Thomas A Davis
Journal:  Biomolecules       Date:  2021-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.